Roche Holding AG Stock News

Roche Holding AG (RHHBY) Q4 2023 Earnings Call Transcript

Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.

Roche said on Thursday that 2024 would see a return to sales growth as it is overcoming a slump in demand for its COVID-19 products and the sales decline of a trio of established cancer drugs is abati

Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.

Speaking at the JPMorgan Healthcare Conference, Roche Pharmaceuticals (RHHBY) CEO Teresa Graham discusses the company's innovation focus and outlook with Yahoo Finance's Anjalee Khemlani. Graham says

ASML dominates an incredibly valuable niche in the semiconductor supply chain. Pharmaceutical giant Roche sports an impressive product pipeline and attractive valuation.

Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.

Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.

I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends.

The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.

Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.

Only the small-cap Russell 2000 managed to stay above zero the entire trading day.